Mylan Acquires Merck KGaA’s Generics Businesses

Mylan, Inc. has acquired Merck KGaA’s Central and Eastern Europe (CEE) generics businesses, which include operations in Poland, Hungary, Slovakia, Slovenia and the Czech Republic. Mylan exercised its option to acquire these businesses as part of a previous agreement from October 2007 in which Mylan acquired Merck KGaA’s generics business (Merck Generics) in Western Europe, Asia-Pacific, Africa and North America.
   
“Our acquisition of the CEE businesses gives us access to an additional area with significant growth opportunities for generics,” said Mylan vice chairman and chief executive officer, Robert J. Coury. “It reflects our global strategy to leverage existing platforms, rather than create start-up organizations. In that respect, we believe the CEE businesses will benefit significantly from Mylan’s scale, vertical and horizontal integration, and robust product portfolio.”
   
“My team and I are excited to have back the CEE businesses, which I helped establish when I was a part of the Merck Generics organization,” said Didier Barret, president of Mylan Europe, Middle East and Africa. “We’re eager to continue to build upon our pan-European presence and execute the growth strategies we’ve always had in mind for this region.”